June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
A randomized crossover study comparing efficacy of fixed-combination travoprost and timolol, and bimatoprost in open-angle glaucoma
Author Affiliations & Notes
  • Wataru Yamada
    Ophthalmology, Gifu University Graduate School of Medicine, Gifu, Japan
  • Akira Sawada
    Ophthalmology, Gifu University Graduate School of Medicine, Gifu, Japan
  • Tetsuya Yamamoto
    Ophthalmology, Gifu University Graduate School of Medicine, Gifu, Japan
  • Footnotes
    Commercial Relationships Wataru Yamada, None; Akira Sawada, None; Tetsuya Yamamoto, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5701. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wataru Yamada, Akira Sawada, Tetsuya Yamamoto; A randomized crossover study comparing efficacy of fixed-combination travoprost and timolol, and bimatoprost in open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5701. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the intraocular pressure (IOP) lowering efficacy of fixed-combination travoprost and timolol, and bimatoprost 0.03% in eyes with open-angle glaucoma (OAG).

Methods: This was a prospective, open-label, randomized, and crossover clinical trial of 54 OAG patients who were receiving treatment either fixed-combination travoprost and timolol or bimatoprost each given once every evening for 8 weeks, after which they were crossed over to the other medication for another 8 weeks. Visits were at baseline, weeks 2, 4, 8, 10, 12, 16. At untreated baseline and at the end of each treatment period the IOP was measured at 10 AM, noon, and 4 PM in a sitting position with Goldmann applanation tonometry. One eye was randomly chosen for further analyses. The IOP-reducing effect of the medications was assessed by the reduction in IOP after 8 weeks of treatment compared with baseline.

Results: Fifty-four OAG patients participated, and two subjects were discontinued this study. The mean baseline IOP was 13.3 ± 1.5 mmHg. Bimatoprost reduced IOP by 2.0 ± 1.5 mm Hg (14.5 ± 10.9 %) and fixed-combination travoprost and timolol by 2.2 ± 1.4 mm Hg (16.2 ± 9.7 %) from the baseline. There were no significant differences in IOP reduction between the two groups (P=0.147). Ocular hyperemia was the most frequently developed adverse event, which was seen in 24 patients (46.2%) treated with bimatoprost as compared with 23 patients (44.2%) treated with fixed-combination travoprost and timolol (P=0.904), followed by hypertrichosis and hyperpigmentation of the eye lid.

Conclusions: Bimatoprost was similarly effective in reducing IOP compared with fixed-combination travoprost and timolol in glaucoma patients with relatively low IOP.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×